TY - STD TI - Hepatitis C. 2015. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. [Accessed 8/27/2015]. UR - http://www.who.int/mediacentre/factsheets/fs164/en/ ID - ref1 ER - TY - CHAP PY - 2011 DA - 2011// TI - Notes from the field: risk factors for hepatitis C virus infections among young adults—Massachusetts, 2010 BT - MMWR ID - ref2 ER - TY - CHAP PY - 2011 DA - 2011// TI - Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men New York City, 2005–2010 BT - MMWR ID - ref3 ER - TY - JOUR AU - Simmons, B. PY - 2015 DA - 2015// TI - Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response JO - Clin Infect Dis VL - 61 UR - https://doi.org/10.1093/cid/civ396 DO - 10.1093/cid/civ396 ID - Simmons2015 ER - TY - JOUR AU - Afdhal, N. PY - 2014 DA - 2014// TI - Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1316366 DO - 10.1056/NEJMoa1316366 ID - Afdhal2014 ER - TY - JOUR AU - Afdhal, N. PY - 2014 DA - 2014// TI - Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1402454 DO - 10.1056/NEJMoa1402454 ID - Afdhal2014 ER - TY - STD TI - Cousien A et al. Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology. 2015;63(4):1090-101. ID - ref7 ER - TY - STD TI - Trooskin SB, Reynolds H, Kostman JR. Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy. Clin Infect Dis. 2015;61(12):1825-30. ID - ref8 ER - TY - JOUR AU - Nuys, K. PY - 2015 DA - 2015// TI - Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern JO - Health Aff (Millwood) VL - 34 UR - https://doi.org/10.1377/hlthaff.2014.1193 DO - 10.1377/hlthaff.2014.1193 ID - Nuys2015 ER - TY - STD TI - Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens. Available from: http://www.hcvguidelines.org/full-report/overview-cost-reimbursement-and-cost-effectiveness-considerations-hepatitis-c-treatment. [Accessed 10/20/15]. UR - http://www.hcvguidelines.org/full-report/overview-cost-reimbursement-and-cost-effectiveness-considerations-hepatitis-c-treatment ID - ref10 ER - TY - BOOK PY - 2005 DA - 2005// TI - Follow The Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain ID - ref11 ER - TY - BOOK PY - 2007 DA - 2007// TI - Prescription Drug Pricing in the Private Sector ID - ref12 ER - TY - STD TI - Silverman E. U.S. Could Save up to $16B if Medicare Part D Prices are Negotiated: Paper. NYC, NY: The Wall Street Journal Blog; 2015. ID - ref13 ER - TY - STD TI - Center for Medicare Advocacy. Part D/Prescription Drug Benefits. Available from: http://www.medicareadvocacy.org/medicare-info/medicare-part-d/- covered%20drugs. [Accessed 10/28/15]. UR - http://www.medicareadvocacy.org/medicare-info/medicare-part-d/ ID - ref14 ER - TY - STD TI - Pollack A. Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion. NYC, NY: The New York Times; 2015. ID - ref15 ER - TY - STD TI - Silverman, E. What the ‘Shocking’ Gilead Discounts on its Hepatitis C Drugs Will Mean. NYC, NY: The Wall Street Journal; 2015. ID - ref16 ER - TY - JOUR AU - Graham, C. S. AU - Swan, T. PY - 2015 DA - 2015// TI - A path to eradication of hepatitis C in low- and middle-income countries JO - Antiviral Res VL - 119 UR - https://doi.org/10.1016/j.antiviral.2015.01.004 DO - 10.1016/j.antiviral.2015.01.004 ID - Graham2015 ER - TY - JOUR AU - Kamal-Yanni, M. PY - 2015 DA - 2015// TI - Hepatitis C drug affordability JO - Lancet Glob Health VL - 3 UR - https://doi.org/10.1016/S2214-109X(14)70365-1 DO - 10.1016/S2214-109X(14)70365-1 ID - Kamal-Yanni2015 ER - TY - BOOK PY - 2003 DA - 2003// TI - Cost-Containment Mechanisms for Essential Medicines, Including Antiretrovirals, in China - Health Economics and Drugs Series No. 013 ID - ref19 ER - TY - BOOK PY - 2015 DA - 2015// TI - CHRONIC HEPATITIS C TREATMENT EXPANSION Generic Manufacturing for Developing Countries ID - ref20 ER - TY - BOOK PY - 2015 DA - 2015// TI - HCV Developing World Strategy ID - ref21 ER - TY - BOOK PY - 2015 DA - 2015// TI - Gilead Denied Patent for Hepatitis C Drug Sofosbuvir in India ID - ref22 ER - TY - STD TI - Borders DW. China Rejects Gilead Patent on Hepatitis C Drug Sofosbuvir 6/19/2015. Available from http://www.doctorswithoutborders.org/article/china-rejects-gilead-patent-hepatitis-c-drug-sofosbuvir. Accessed 3/6/2016. UR - http://www.doctorswithoutborders.org/article/china-rejects-gilead-patent-hepatitis-c-drug-sofosbuvir ID - ref23 ER - TY - STD TI - Chhatwal J, He T, Lopez-Olivo MA. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics. 2016. [epub ahead of print]. ID - ref24 ER - TY - JOUR AU - Najafzadeh, M. PY - 2015 DA - 2015// TI - Cost-effectiveness of novel regimens for the treatment of hepatitis C virus JO - Ann Intern Med VL - 162 UR - https://doi.org/10.7326/M14-1152 DO - 10.7326/M14-1152 ID - Najafzadeh2015 ER - TY - JOUR AU - Leidner, A. J. PY - 2015 DA - 2015// TI - Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27736 DO - 10.1002/hep.27736 ID - Leidner2015 ER - TY - JOUR AU - Linas, B. P. PY - 2015 DA - 2015// TI - The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection JO - Ann Intern Med VL - 162 UR - https://doi.org/10.7326/M14-1313 DO - 10.7326/M14-1313 ID - Linas2015 ER - TY - JOUR AU - Everson, G. T. PY - 2015 DA - 2015// TI - Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial JO - Ann Intern Med VL - 163 UR - https://doi.org/10.7326/M15-1000 DO - 10.7326/M15-1000 ID - Everson2015 ER - TY - JOUR AU - Feld, J. J. PY - 2015 DA - 2015// TI - Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1512610 DO - 10.1056/NEJMoa1512610 ID - Feld2015 ER - TY - JOUR AU - Foster, G. R. PY - 2015 DA - 2015// TI - Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1512612 DO - 10.1056/NEJMoa1512612 ID - Foster2015 ER - TY - JOUR AU - Barua, S. PY - 2015 DA - 2015// TI - Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States JO - Ann Intern Med VL - 163 UR - https://doi.org/10.7326/M15-0406 DO - 10.7326/M15-0406 ID - Barua2015 ER - TY - BOOK PY - 2015 DA - 2015// TI - HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C ID - ref32 ER - TY - STD TI - Silverman E. Gilead Limits Enrollment in its Hep C Patient Programs to Pressure Insurers. NYC, NY: The Wall Street Journal Blog; 2015. ID - ref33 ER -